GENERIC AND BIOSIMILAR MEDICINES, CENTRAL TO PATIENT HEALTH AND GLOBAL HEALTHCARE POLICIESSEPTEMBER 9, 2022 @ 11.01PM
Experts and leaders from the local and global generic and biosimilar medicines industry, government and UN agencies, patient organisations, academia and other stakeholders met recently to discuss key topics affecting worldwide patient access to affordable medicines.
The conference covered key aspects such as the need for long-term investment in health, the off-patent medicines industry‘s vital role for healthcare resilience; the importance of a globally resilient supply chain and trade facilitating measures, as well as a balanced IP environment; challenges and opportunities of digitalisation and technological innovation; need for regulatory agility, reliance and harmonisation as demonstrated during the Covid-19 health crisis; effective strategies to advance global access to treatments for Non-Communicable Diseases, and trends and policies that shape the competitive market environment, impacting the sustainability of the off-patent pharmaceutical sector, and hence medium and long-term reliable and affordable access to essential medicines. “This year’s annual conference is the first ever conference by the International Generic and Biosimilar Medicines Association (IGBA) in the South-East Asia Region and is hosted by our Associate Member, the Malaysian Organisation of Pharmaceutical Industries (MOPI),” commented Vivian Frittelli, IGBA Chair. “The generic and biosimilar medicines industry played a crucial role during the pandemic and is the biggest supplier of quality-assured medicines around the world, while reducing the pressure on healthcare budgets. Governments need to work together with all relevant stakeholders, to ensure that quality-assured medicines remain available, affordable, and accessible for patients, and reduce the risk of medicines shortages,” Frittelli added. “We are proud to host this joint international conference in Kuala Lumpur,” commented Billy Urudra, MOPI President. “The South East Asian (SEA) market is one of the fastest growing pharmaceutical markets in the world. It is crucial that the countries in this region continue to promote policies to support the growth of the generic and biosimilar medicines industry, while ensuring healthy market competition, progressing the ASEAN regulatory harmonisation efforts and preserving patient access,” Urudra concluded. 
|
Roche launch Perjeta - Herceptin combination, a post surgery treatment for early breast cancer (eBC)
Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer
|
- IN THE SPOTLIGHT
-
HEALTH CONDITIONS
- ANTIMICROBIAL RESISTANCE
- ARTHRITIS
- ASTHMA
- BACK PAIN
- BRAIN DISORDERS
- BREAST CANCER
- CANCER
- CARDIOVASCULAR DISEASE
- CERVICAL CANCER
- CORONAVIRUS DISEASE (COVID-19)
- DEMENTIA
- DENGUE
- DENTAL PROBLEMS
- DIABETES
- DRUG ABUSE
- ECZEMA
- EPILEPSY
- EYE
- FIBROIDS
- GASTROINTESTINAL DISEASES
- INFLUENZA (FLU)
- HEADACHES & MIGRAINES
- HEPATITIS
- HIV & AIDS
- JOINT PAIN
- KIDNEY DISEASE
- LUNG CANCER
- LUPUS
- MELASMA
- MENTAL HEALTH
- MOUTH-AND-TEETH
- OBESITY
- OSTEOPOROSIS
- OVARIAN DYSFUNCTION: UNDERSTANDING PREMATURE OVARIAN FAILURE, POLYCYSTIC OVARY DISEASE AND INFERTILITY
- SEXUAL & REPRODUCTIVE HEALTH
- SKIN CONDITIONS
- SLEEP
- STROKE
- DISABILITIES & SPECIAL ABILITIES
- NURSING RESOURCES
- DIGITAL HEALTH
- HEALTH PRODUCTS & SERVICES
- RELATIONSHIPS
- FAMILY HEALTH & PARENTING
- EMPOWERING WOMEN
- MEN'S WELLNESS
- GOLDEN YEARS
- ACTIVE LIFE HUB
- NUTRITION
- COMPLIMENTARY MEDICINE
- HUMANITARIAN & COMMUNITY HEALTH
- AMBULANCE AND FIRST AID GUIDE
- Community clinics/ Klinik Komuniti
- Government Dental Clinics / Klinik Pergigian Kerajaan
- ABOUT US
